USE OF FLT3 CAR-T CELLS AND FLT3 INHIBITORS TO TREAT ACUTE MYELOID LEUKEMIA

摘要

The invention generally relates to the treatment of cancer with FLT3 targeting agents and kinase inhibitors. In particular, the invention relates to adoptive immunotherapy of Acute Myeloid Leukemia (AML) with chimeric antigen receptor (CAR)-modified T cells specific for FMS-like tyrosine kinase (FLT3) in combination with FLT3 inhibitors.